S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)

MoonLake Immunotherapeutics (MLTX) Competitors

$27.55
+0.34 (+1.25%)
(As of 06/1/2023 ET)
Compare
Today's Range
$26.31
$27.69
50-Day Range
$19.01
$28.54
52-Week Range
$4.48
$30.30
Volume
189,000 shs
Average Volume
289,307 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.29

MLTX vs. RCUS, PTGX, KROS, DICE, DVAX, GMTX, AGIO, SNDX, ZNTL, and TARO

Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Arcus Biosciences (RCUS), Protagonist Therapeutics (PTGX), Keros Therapeutics (KROS), DICE Therapeutics (DICE), Dynavax Technologies (DVAX), Gemini Therapeutics (GMTX), Agios Pharmaceuticals (AGIO), Syndax Pharmaceuticals (SNDX), Zentalis Pharmaceuticals (ZNTL), and Taro Pharmaceutical Industries (TARO). These companies are all part of the "pharmaceutical preparations" industry.

MoonLake Immunotherapeutics vs.

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

MoonLake Immunotherapeutics has higher earnings, but lower revenue than Arcus Biosciences. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$49.97 million-$1.15-23.96
Arcus Biosciences$112 million13.25-$267 million-$3.85-5.27

Arcus Biosciences received 153 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 83.33% of users gave MoonLake Immunotherapeutics an outperform vote while only 63.16% of users gave Arcus Biosciences an outperform vote.

CompanyUnderperformOutperform
MoonLake ImmunotherapeuticsOutperform Votes
15
83.33%
Underperform Votes
3
16.67%
Arcus BiosciencesOutperform Votes
168
63.16%
Underperform Votes
98
36.84%

76.1% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 73.0% of Arcus Biosciences shares are held by institutional investors. 15.3% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 13.8% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics presently has a consensus target price of $25.29, indicating a potential downside of 8.22%. Arcus Biosciences has a consensus target price of $41.44, indicating a potential upside of 104.16%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
3.00
Arcus Biosciences
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

MoonLake Immunotherapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.

In the previous week, Arcus Biosciences had 11 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 15 mentions for Arcus Biosciences and 4 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.34 beat Arcus Biosciences' score of 0.11 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcus Biosciences
3 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -233.41%. Arcus Biosciences' return on equity of -41.22% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake Immunotherapeutics N/A -56.52% -52.13%
Arcus Biosciences -233.41% -41.22% -20.37%

Summary

MoonLake Immunotherapeutics beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLTX vs. The Competition

MetricMoonLake ImmunotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.45B$5.82B$4.54B$6.20B
Dividend YieldN/A2.74%2.42%6.15%
P/E Ratio-23.964.87100.6311.94
Price / SalesN/A326.473,636.6695.58
Price / CashN/A20.1190.91108.26
Price / Book24.605.435.157.27
Net Income-$49.97M$190.11M$117.81M$193.48M
7 Day Performance-3.47%8.11%3.21%2.60%
1 Month Performance21.37%7.79%3.14%3.08%
1 Year Performance267.33%23.71%23.11%1.73%

MoonLake Immunotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCUS
Arcus Biosciences
2.0224 of 5 stars
$20.24
-8.1%
$41.44
+104.8%
+8.4%$1.48B$119M-5.26366
PTGX
Protagonist Therapeutics
2.2478 of 5 stars
$25.47
-3.0%
$35.67
+40.0%
+197.6%$1.46B$26.58M-8.97118
KROS
Keros Therapeutics
2.3306 of 5 stars
$48.64
-1.0%
$103.75
+113.3%
+41.6%$1.45B$20.10M-11.0560Positive News
DICE
DICE Therapeutics
2.0383 of 5 stars
$31.46
-4.1%
$62.60
+99.0%
+129.9%$1.50B$1.13M-14.4346Short Interest ↓
DVAX
Dynavax Technologies
2.4452 of 5 stars
$11.23
+0.3%
$24.00
+113.7%
-3.6%$1.43B$722.68M7.20311Positive News
GMTX
Gemini Therapeutics
0 of 5 stars
$32.53
+1.5%
N/A+2,489.8%$1.41BN/A-32.5331Gap Up
AGIO
Agios Pharmaceuticals
2.0074 of 5 stars
$25.32
-1.9%
$37.00
+46.1%
+29.8%$1.41B$14.24M-6.38390Positive News
SNDX
Syndax Pharmaceuticals
2.4258 of 5 stars
$19.91
-0.5%
$33.86
+70.1%
+21.0%$1.37B$139.71M-8.2659Positive News
ZNTL
Zentalis Pharmaceuticals
1.6149 of 5 stars
$26.46
-11.9%
$46.60
+76.1%
+8.0%$1.57BN/A-6.17177Insider Selling
High Trading Volume
TARO
Taro Pharmaceutical Industries
1.5463 of 5 stars
$36.10
+22.8%
$35.00
-3.0%
+0.8%$1.36B$572.95M53.881,455Gap Up
High Trading Volume

Related Companies and Tools

This page (NASDAQ:MLTX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -